MARKET

GRFS

GRFS

Grifols
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.51
+0.31
+1.70%
After Hours: 18.50 -0.01 -0.05% 17:39 10/23 EDT
OPEN
18.31
PREV CLOSE
18.20
HIGH
18.56
LOW
18.22
VOLUME
1.29M
TURNOVER
--
52 WEEK HIGH
25.73
52 WEEK LOW
13.40
MARKET CAP
4.78B
P/E (TTM)
20.31
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
SNBR, GRFS among premarket gainers
SPI Energy (SPI) +56% on entering agreement with Shaanxi Tongjia Automobile.Anavex Life Sciences (AVXL) +36% after completing mid-stage study of lead drug in rare brain development disorder.Organogenesis Holdings (ORGO) +27% on Q3 preliminary results.Huttig Building Products
Seekingalpha · 10/15 12:24
European markets tumble as stimulus hopes fade and coronavirus surges; Stoxx 600 down 1.9%
European stocks fell sharply on Thursday as hopes fade that a U.S. stimulus package will be agreed before the November election.
CNBC.com · 10/15 05:08
Benzinga Pro's Top 5 Stocks To Watch For Friday, Oct. 9, 2020: JPM, JNPR, VLDR, GNMK, GRFS
Today's 5 Stock Ideas:  JP Morgan (JPM) - Will unofficially kick off the Q3 earnings season next week on Tuesday. Citigroup (C) will also report results on that day. Bank Of America
Benzinga · 10/09 12:36
Grifols on go with hyperimmune globulin trial for COVID-19
Grifols (GRFS) has started a randomized clinical trial to test the safety, efficacy and tolerability of its anti-SARS-CoV-2 hyperimmune globulin, a potential treatment for COVID-19.This medicine provides a high and
Seekingalpha · 10/09 11:06
Grifols' anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing people's health and well-being, today announced that its anti-SARS-CoV-2 hyperimmune globulin, a potential treatment for COVID-19, has started a randomized controlled clinical trial to test its safety, efficacy and tolerability. This medicine provides a high and consistent concentration of purified neutralizing antibodies and could be used for both prevention and treatment of the disease. The study is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).
PR Newswire · 10/09 10:30
Takeda in group trial for COVID-19 hyperimmune convalescent plasma treatment
Takeda (TAK) is among a group of companies who have begun testing an experimental COVID-19 treatment derived from convalescent plasma of those recovered from the disease. The study, funded by
Seekingalpha · 10/09 05:16
Is Grifols SA (GRFS) Going to Burn These Hedge Funds?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually
Insider Monkey · 10/07 17:45
Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.
\\- The investment includes a fractionation plant with a 1.5 million-liter annual capacity and two purification plants, making Grifols the only large-scale commercial manufacturer of plasma products in Canada\\- This transaction highlights Grifols' commitment to supporting countries
CNW Group · 10/01 16:13
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GRFS. Analyze the recent business situations of Grifols through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GRFS stock price target is 25.00 with a high estimate of 25.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 277
Institutional Holdings: 128.72M
% Owned: 49.89%
Shares Outstanding: 258.01M
TypeInstitutionsShares
Increased
63
18.38M
New
58
-9.37M
Decreased
61
8.96M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.74%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Non-Executive Chairman
Victor Grifols Roura
Co-Chief Executive Officer/Executive Director
Victor Grifols Deu
Co-Chief Executive Officer/Executive Director
Raimon Grifols Roura
Non-Executive Vice Chairman
Thomas Daga Glanzmann
Non-Executive Vice Chairman
Thomas Glanzmann
Chief Financial Officer
Alfredo Arroyo Guerra
Corporate Executive
PETER ALLEN
Corporate Executive
Joel Abelson
Corporate Executive
Albert Coma-Cros
Corporate Executive
Gregory Gene Rich
Corporate Executive
Albert Grifols Roura
Corporate Executive
Eduardo Raimundo Herrero Jimenez
Corporate Executive
ROBERT JAGT
Corporate Executive
Jose Oriol Dunach
Corporate Executive
Miguel Pascual Montblanch
Corporate Executive
Carsten Schroeder
Chief Human Resource Officer
Mateo Borras Humbert
Chief Technology Officer
Javier Sueiras Gil
Vice President
Vicente Blanquer Torre
Vice President
Matt Murawski
Vice President
Nuria Pascual Lapena
Vice President
Teresa Rione
General Counsel
David Bell
Managing Director
Luis Twose Garcon
Other
Daniel Fleta
Other
Lafmin Morgan
Secretary
Nuria Martin Barnes
Assistant Secretary/Director
Tomas Daga Gelabert
Lead Director/Independent Director
Inigo Sanchez Asiain Mardones
Director
Ramon Riera Roca
Independent Director
Marla Elizabeth Salmon
Independent Director
Enriqueta Felip Font
Independent Director
Luis Isasi Fernandez de Bobadilla
Independent Director
Steven Mayer
Independent Director
Carina Szpilka Lazaro
Independent Director
Belen Villalonga Morenes
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.154155
10/30/2020
10/31/2019
Dividend USD 0.169716
12/02/2019
05/29/2019
Dividend USD 0.175638
06/07/2019
11/07/2018
Dividend USD 0.22789
11/30/2018
05/25/2018
Dividend USD 0.250975
06/01/2018
--
Dividend USD 0.212979
12/01/2017
--
Dividend USD 0.163528
05/30/2017
--
Dividend USD 0.193644
12/05/2016
--
Dividend USD 0.162059
06/02/2016
--
Dividend USD 0.384765
12/10/2015
--
Dividend USD 0.341846
06/08/2015
--
Dividend USD 0.312792
12/04/2014
05/30/2014
Dividend USD 0.286887
06/05/2014
05/24/2013
Dividend USD 0.258668
06/05/2013
05/17/2013
Dividend USD 0.01283
05/29/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GRFS
Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma for therapeutic use. The Hospital division offers non-biological pharmaceutical products and medical supplies for hospital pharmacy. The Diagnostic division provides clinical analysis and laboratory testing tools to laboratories, hospitals and blood banks. The Raw materials division includes sales of intermediate biological products, as well as manufacturing services to third parties. The Company operates production facilities in Spain, the United States, Mexico and Australia, among others. It controls numerous subsidiaries, such as Kiro Grifols SL.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Grifols SA - ADR stock information, including NASDAQ:GRFS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRFS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GRFS stock methods without spending real money on the virtual paper trading platform.